IRIS
Del Re, Marzia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.427
NA - Nord America 2.222
SA - Sud America 782
EU - Europa 452
Continente sconosciuto - Info sul continente non disponibili 209
AF - Africa 108
OC - Oceania 4
Totale 6.204
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.022
SG - Singapore 757
BR - Brasile 594
CN - Cina 476
BD - Bangladesh 340
HK - Hong Kong 328
IT - Italia 288
VN - Vietnam 158
MX - Messico 107
IN - India 82
AR - Argentina 61
IQ - Iraq 55
CA - Canada 49
CO - Colombia 43
TR - Turchia 38
ID - Indonesia 30
EC - Ecuador 29
SA - Arabia Saudita 27
RU - Federazione Russa 26
ZA - Sudafrica 24
PK - Pakistan 23
VE - Venezuela 23
GB - Regno Unito 22
PH - Filippine 19
FR - Francia 18
NL - Olanda 18
MA - Marocco 15
MY - Malesia 14
UZ - Uzbekistan 14
UA - Ucraina 13
ES - Italia 12
DE - Germania 11
JM - Giamaica 11
TN - Tunisia 11
CR - Costa Rica 10
DZ - Algeria 10
JO - Giordania 9
KE - Kenya 9
PY - Paraguay 9
EG - Egitto 8
BO - Bolivia 7
TT - Trinidad e Tobago 7
AZ - Azerbaigian 6
CL - Cile 6
PS - Palestinian Territory 6
RS - Serbia 6
KZ - Kazakistan 5
NP - Nepal 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
AO - Angola 4
HN - Honduras 4
HU - Ungheria 4
IE - Irlanda 4
IR - Iran 4
LB - Libano 4
NG - Nigeria 4
PE - Perù 4
ET - Etiopia 3
NI - Nicaragua 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
TH - Thailandia 3
ZW - Zimbabwe 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
BE - Belgio 2
BG - Bulgaria 2
BH - Bahrain 2
BY - Bielorussia 2
CG - Congo 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
FI - Finlandia 2
GE - Georgia 2
IL - Israele 2
KR - Corea 2
LT - Lituania 2
LY - Libia 2
MU - Mauritius 2
PL - Polonia 2
RO - Romania 2
SN - Senegal 2
SV - El Salvador 2
UG - Uganda 2
AM - Armenia 1
BB - Barbados 1
CH - Svizzera 1
CM - Camerun 1
CY - Cipro 1
GM - Gambi 1
GP - Guadalupe 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
JP - Giappone 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
Totale 5.979
Salva come PNG Salva come JPEG
Città #
San Jose 1.084
Singapore 445
Hong Kong 320
Ashburn 316
Beijing 239
Santa Clara 108
Mexico City 87
Ho Chi Minh City 72
Rome 61
New York 39
São Paulo 29
Hanoi 27
Milan 27
Los Angeles 22
Rio de Janeiro 22
Buffalo 18
Istanbul 15
Baghdad 13
Brasília 13
Chicago 13
Lahore 13
Medellín 13
Caracas 12
Curitiba 12
Dhaka 12
Naples 12
Tashkent 12
Bogotá 11
Council Bluffs 11
Dallas 11
Belo Horizonte 10
Jeddah 10
Orem 10
Quito 10
Ribeirão Preto 10
Amman 9
Haiphong 9
Nairobi 9
Guayaquil 8
Moscow 8
Riyadh 8
Campinas 7
Goiânia 7
Jakarta 7
San José 7
São José dos Campos 7
Tunis 7
Asunción 6
Atlanta 6
Baku 6
Bari 6
Charlotte 6
Da Nang 6
Erbil 6
Houston 6
Johannesburg 6
Karbala 6
Kuala Lumpur 6
London 6
Osasco 6
Salvador 6
Toronto 6
Belém 5
Biên Hòa 5
Bologna 5
Buenos Aires 5
Canoas 5
Cape Town 5
Catania 5
Fortaleza 5
Hyderabad 5
Kingston 5
Kirkuk 5
La Paz 5
Porto Alegre 5
Anápolis 4
Bauru 4
Belgrade 4
Cagliari 4
Casablanca 4
Ceres 4
Cleveland 4
Dammam 4
Feira de Santana 4
Guarulhos 4
Kathmandu 4
Lima 4
Manaus 4
Medina 4
Montevideo 4
Montreal 4
New Delhi 4
Niterói 4
Orlando 4
Pelotas 4
Pune 4
Quezon City 4
Rabat 4
Rondonópolis 4
San Antonio 4
Totale 3.487
Salva come PNG Salva come JPEG
Nome #
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours 77
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer 71
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients 65
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide 60
Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool 56
Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma 56
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance 54
Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: A systematic review protocol 53
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer 53
The Role of ctDNA for Diagnosis and Histological Prediction in Early Stage Non-Small-Cell Lung Cancer: A Narrative Review 53
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view 52
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 52
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients 51
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 50
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 50
Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation 49
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies 48
Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review 48
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 47
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 47
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences 47
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival 46
Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer 46
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors 45
EGFR signaling pathway as therapeutic target in human cancers 45
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs 44
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives 43
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines 43
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 43
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 42
The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies 41
β3-adREnoceptor Analysis in CORD Blood of Neonates (β3 RECORD): Study Protocol of a Pilot Clinical Investigation 40
Recommendations for using molecular assays on liquid biopsy: the first document provided by intersociety Group AIOM, SIF, SIAPEC-IAP, SIBioC | Raccomandazioni per l’esecuzione di indagini molecolari su biopsia liquida in oncologia 40
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 40
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series 39
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer 38
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 38
ANKRd44 gene silencing: A putative role in trastuzumab resistance in HER2-like breast cancer 38
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients 38
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 37
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 37
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 37
Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA 36
Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years 36
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis 36
Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data 36
Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins 35
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated Acute Myeloid Leukemia (AML) to guide treatment strategy 35
Facing an un-met need in lung cancer screening: The never smokers 35
Updates on liquid biopsy: Current trends and future perspectives for clinical application in solid tumors 35
Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatments 35
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies 35
Empower the potential of trastuzumab deruxtecan with novel combinations 35
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 35
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment 34
Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice 34
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 34
The Genetic Basis of Dormancy and Awakening in Cutaneous Metastatic Melanoma 33
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib 33
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 33
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 33
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 33
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 33
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 33
Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives 33
What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA 32
TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma 32
Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting 32
Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project 32
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 32
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors 31
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study 31
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 31
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data 31
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 31
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards 31
A real-world application of liquid biopsy in metastatic colorectal cancer: The poseidon study 31
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST) 31
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression 31
Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients 31
Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes 31
Cross-Linked Hyaluronic Acid as Tear Film Substitute 31
Author's reply. Should CYP2D6 be genotyped when treating with tamoxifen? Pharmacogenomics 31
Recurrent USP6 rearrangement in a subset of atypical myofibroblastic tumours of the soft tissues: low-grade myofibroblastic sarcoma or atypical/malignant nodular fasciitis? 30
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report 30
Author's reply 30
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 30
Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics 30
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 30
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC 30
Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors 30
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 29
Genomics in Lung Cancer: A Scoping Review of the Role of ctDNA in Non-Advanced Non-Small-Cell Lung Cancer in the Prediction of Prognosis After Multimodality Therapeutic Approaches 29
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 29
The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences 29
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide 29
Genome Wide Association Studies (GWAS) 29
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer 29
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment 29
Should CYP2D6 be genotyped when treating with tamoxifen? 29
Totale 3.853
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.237
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.237
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20251.169 0 0 0 44 19 50 69 149 168 33 309 328
2025/20264.716 176 38 271 244 467 265 441 256 1.089 555 499 415
2026/2027319 149 148 22 0 0 0 0 0 0 0 0 0
Totale 6.204